1713 A MULTIPLEXED, PARTICLE BASED FLOW CYTOMETRIC ASSAY IDENTIFIED MMP7 TO BE ASSOCIATED WITH CANCER RELATED DEATH AMONG PATIENTS WITH BLADDER CANCER
Robert Svatek,Jinliang Xing,David Chang,Jay Shah,Jie Lin,David McConkey,Xifeng Wu,Colin Dinney
DOI: https://doi.org/10.1016/j.juro.2010.02.1560
2010-01-01
Abstract:You have accessJournal of UrologyBladder Cancer: Invasive/Metastatic Disease II1 Apr 20101713 A MULTIPLEXED, PARTICLE BASED FLOW CYTOMETRIC ASSAY IDENTIFIED MMP7 TO BE ASSOCIATED WITH CANCER RELATED DEATH AMONG PATIENTS WITH BLADDER CANCER Robert Svatek, Jinliang Xing, David Chang, Jay Shah, Jie Lin, David McConkey, Xifeng Wu, and Colin Dinney Robert SvatekRobert Svatek More articles by this author , Jinliang XingJinliang Xing More articles by this author , David ChangDavid Chang More articles by this author , Jay ShahJay Shah More articles by this author , Jie LinJie Lin More articles by this author , David McConkeyDavid McConkey More articles by this author , Xifeng WuXifeng Wu More articles by this author , and Colin DinneyColin Dinney More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1560AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The objective of this study was to demonstrate the utility of a multiplexed, particle based flow cytometric assay for the simultaneous analysis of a panel of matrix metalloproteinases (MMPs) using small volumes of plasma samples from patients with bladder cancer. In addition, we sought to test the hypothesis that plasma levels of MMPs are associated with time to cancer-related death. METHODS Plasma MMP concentrations (MMP-1, -2, -3, -7, -8, -9, and -12) in patients presenting with high-grade <=T1 bladder cancer were measured using a Fluorokine Multi-Analyte Profiling kit and a Luminex Bioanalyzer. Data regarding clinical and pathologic features was ascertained in a retrospective fashion. RESULTS The median follow-up duration was 30.4 months. At the time of analysis, 61 patients had died, including 40 (36.7%) from bladder cancer. Plasma MMP-12 was not measurable. For all other MMPs, the intra-assay coefficient of variation varied from 6.12% to 9.82%. MMPs-1, -2, -3, -8, and -9 were not significantly associated with time to cancer-related death. Plasma MMP-7 levels were significantly associated with time to cancer-related death after adjustment for competing clinical-pathologic features (HR 2.2, 95%CI 1.1-4.5, P=0.022). The 5-yr median survival for those patients with MMP-7 above and below the median value were 66.1% (95%CI 52.5-76.6%) and 29.0% (13.3-46.7%) respectively (P=0.01). CONCLUSIONS Multiplexed, particle-based flow cytometric assay allows for high-throughput measurement of multiple plasma or serum proteins simultaneously. Using this new technology in a cohort of patients with bladder cancer, we identified plasma levels of MMP-7 to be significantly associated time to cancer-related death. Houston, TX© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e661 Peer Review Report Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Robert Svatek More articles by this author Jinliang Xing More articles by this author David Chang More articles by this author Jay Shah More articles by this author Jie Lin More articles by this author David McConkey More articles by this author Xifeng Wu More articles by this author Colin Dinney More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...